Pharma Focus Asia
KP - Sustainable Packaging Solutions

AGC Biologics Invests US$350 bn(¥50bn) to Construct New Manufacturing Site in Yokohama, Japan


AGC Biologics plans to construct a new manufacturing facility in Yokohama Japan. 


The new facility, spanning four storeys and 20,000 square metres, will offer services in mammalian cell culture, messenger RNA, and cell therapy. 

The facility will provide comprehensive services ranging from pre-clinical to commercial stages for mammalian-based protein biologics, cell therapies, and messenger RNA (mRNA) products.

The site will host numerous 2,000 L single-use bioreactors and multiple 4,000 L or larger reactors dedicated to mammalian cell culture services.

This new site forms a crucial component of the strategic growth plan aimed at enhancing high-quality pharmaceutical development and manufacturing services within the Asia region. Its design is specifically geared towards addressing the surging global requirements for biologics and advanced therapy medicinal products (ATMPs).

The facility is projected to commence operations in 2026.


Name    AGC Biologics
Type      New Construction
Budget   US$350 bn(¥50bn)
Year        2026

Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024CPHI Chine || PMEC China 2024Gibco Adherent Kidney Media PanelAsia Healthcare Week 2024CPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?